Drugs / VY-AADC01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03065192 | May 2017 → Aug 2021 | Parkinson disease, movement disorder, neurodegenerative disease | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT01973543 | Oct 2013 → Jan 2020 | Parkinson disease | Neurocrine Biosciences | Completed | No outcome recorded |
Press releases naming this drug 9 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VY-AADC-01 | “The investigational drug, termed VY-AADC-01, will be injected directly into the striatum during a neurosurgical procedure that is performed with real-time MRI imaging to...” NCT03065192 ↗ |
| Known as | NBIb-1817 | “BACKGROUND AND OBJECTIVES: To report final, 36-month safety and clinical outcomes from the PD-1101 trial of NBIb-1817 (VY-AADC01) in participants with moderately advanced...” PMID 34649873 ↗ Oct 2021 |
| Modality | Gene therapy (AAV / viral vector) | “VY-AADC01, an experimental AAV2 gene therapy encoding the human aromatic l-amino acid decarboxylase (AADC) enzyme.” PMID 34649873 ↗ Oct 2021 |
| Route | Other | “This investigational drug, termed VY-AADC01, will be injected directly into the striatum during a neurosurgical procedure” NCT01973543 ↗ |